# A Study of DZD8586 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (TAI-SHAN1)

> **NCT05844956** · PHASE1,PHASE2 · COMPLETED · sponsor: **Dizal Pharmaceuticals** · enrollment: 17 (actual)

## Conditions studied

- Lymphoma, Non-Hodgkin

## Interventions

- **DRUG:** DZD8586

## Key facts

- **NCT ID:** NCT05844956
- **Lead sponsor:** Dizal Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-01
- **Primary completion:** 2024-02-29
- **Final completion:** 2024-02-29
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2025-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05844956

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05844956, "A Study of DZD8586 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (TAI-SHAN1)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05844956. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*